About this document

PBRER E2C(R2) Draft Guideline Overview by haroonmohammed588 is a document available to read on EtoBox.

The Periodic Benefit-Risk Evaluation Report (PBRER) guideline aims to standardize the reporting of benefit-risk evaluations for marketed pharmaceuticals across ICH regions, including the EU, Japan, and the USA. It emphasizes the need for ongoing analysis of safety and efficacy information throughout a product

Author

haroonmohammed588

Language

EN